Prevention of diabetes through induction of immunological tolerance

• US 7,361,333 B2
• Filed: 09/12/2003
• Issued: 04/22/2008
• Est. Priority Date: 10/26/1995
• Status: Expired due to Fees

• Current Assignee: Paul P. Latta
• Original Assignee: Paul P. Latta
• Inventors: Latta, Paul P.
• Primary Examiner(s): BELYAVSKYI, MICHAIL A
• Application Number:
  US10/660,924
• Publication Number:
  US 20040047848A1
• Time in Patent Office: 1,684 Days
• Field of Search: 424/93.1, 424/93.7
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 2035/128 capsules, e.g. microcapsules
• CPC Class Codes: A61K 2039/515 Animal cells
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 39/001 Preparations to induce tolerance to non-self, e.g. prior to transplantation
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 5/0677 Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Abstract

A method of creating tolerance to transplanted cells, tissue, or organs without the need for continuous immunosuppression. A tolerizing dose of a cell or tissue within a membrane structure is implanted into a patient. Once the patient becomes tolerant to the cell or tissue, a tissue or organ is implanted which will no longer be recognized as foreign matter. The method makes animal organs practical for human use, prevents autoimmune destruction as well as immune rejection. It has applications in treatment and prevention of many mammalian diseases.

Claims

1. A method of preventing onset of Type I diabetes in a mammal predisposed to Type I diabetes, comprising implanting a dose of insulin-producing cells encapsulated in a biologically-compatible membrane into an implantation site in said mammal prior to onset of Type I diabetes, wherein said dose is at least one order of magnitude less than that necessary to achieve normoglycemia in a mammal of the same species with type I diabetes.

2. The method of claim 1, wherein said cells are from a primary cell source.

3. The method of claim 2, wherein said cells are pancreatic islet cells.

4. The method of claim 1, wherein said cells are encapsulated in a conformal coating.

5. The method of claim 4, wherein said conformal coating comprises polyethylene glycol (PEG).

6. The method of claim 1, wherein the insulin-producing cells are from the same species as the mammal.

7. The method of claim 1, wherein Type I diabetes is prevented without continuous immunosuppression.

8. The method of claim 1, wherein the cells are implanted intraperitoneally.